All In Biotech

Drug Trial Radar · NCT05345769

Safety and Efficacy of AM712 in Patients with NAMD

A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and High Concentration Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients with Neovascular Age-related Macular Degeneration.

Last checked: Nov 19, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Apr 28, 2022

Primary completion

Nov 4, 2024

Study completion Nov 4, 2024

Sponsor

Lead sponsor
AffaMed Therapeutics LimitedIndustry
Sponsor type
Industry
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with neovascular age- related macular degeneration (nAMD).

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • AM712(ASKG712)Biological

    AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular adverse events (AEs) of the study eyesTime frame: 252 days
  2. Incidence of non-ocular AEsTime frame: 252 days
  3. Any relevant safety observations derived from BCVATime frame: 252 days
  4. Any relevant safety observations derived from SD-OCTTime frame: 252 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Retina Consultants San Diego

    Poway, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • Colorado Retina

    Lakewood, Colorado

  • Florida Eye Associates

    Melbourne, Florida

  • Retina Research Institute at New England Retina Consultants

    Springfield, Massachusetts

  • Tennessee Retina, PC

    Nashville, Tennessee

  • Retina Consultants of Texas

    Bellaire, Texas

  • Retina Consultants of Texas

    San Antonio, Texas

  • Retina Consultants of Texas

    The Woodlands, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.